CD4 and neoplasm: The efficacy of Mut_48 is thus related to presentation of the CD4+ T cell helper antigen alongside a tumor-specific CTL NeoAg most likely by the same APC, mechanistically consistent with Th-mediated ‘licensing’ of APC to program optimal CD8+ T cell responses (22, 25).